| abstract |
The invention generally relates to a compound of formula I, (R) -N- (3- (7-methyl-1H-indazol-5-yl) -1- (4- (1-methylpiperidin-4-yl) piperazin-1- il) -1-oxopropan-2-yl) -4- (2-oxo-1,2-dihydroquinolin-3-yl) piperidine-1-carboxamide, including pharmaceutically acceptable salts, which is a CGRP receptor antagonist. The invention also relates to pharmaceutical compositions and methods for using the compound in the treatment of CGRP-related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal damage, circulatory shock, menopausal hyperemia, inflammatory respiratory diseases such like asthma, chronic obstructive pulmonary disease (COPD), and cancer. |